International Medical Research Frontier

Objective To discuss the clinical experience of implementing digestive internal medicine treatment for patients with chronic atrophic gastritis. Methods The study spanned one year, from October 2023 to September 2024. A total of 80 patients with chronic atrophic gastritis were treated during this period. 40 patients treated in 2023.10-2024.9 as the control group (received routine treatment) and 40 patients treated in 2023.10-2024.9 as the observation group (received comprehensive digestive internal medicine treatment). The outcomes of different treatments were statistically analyzed, and the differences were observed and compared. Results Under the influence of different treatments, there were significant differences in the treatment outcomes between the two groups. The symptom scores (gastric distension, diarrhea, severe upper abdominal pain, acid regurgitation, belching), and recurrence rates of the observation group were all lower than those of the control group. The clinical efficacy data and Helicobacter pylori negativity rate of the observation group were better than those of the control group, with P values <0.05, indicating comparability. There was no significant difference in the incidence of adverse reactions between the two groups during the treatment period, with P>0.05. Conclusion Comprehensive digestive internal medicine treatment for patients with chronic atrophic gastritis is effective. It can effectively alleviate symptoms such as gastric distension, diarrhea, and severe upper abdominal pain, improve the Helicobacter pylori negativity rate, control recurrence, and has fewer adverse reactions, demonstrating good safety and is worth adopting.

Chronic atrophic gastritis; Gastroenterology; Clinical treatment; Recurrence rate